S. Korea’s SK Pharma Draws On Government Support For Epilepsy Drug
This article was originally published in PharmAsia News
Executive Summary
South Korea’s SK Pharmaceuticals plans to draw on government backing to conduct Phase II trials of epilepsy in India, Poland and the U.S.